Abstract
Despite best practices, recurrence following transarterial chemoembolization is still common as hepatocellular carcinoma (HCC) cells undergo metabolic reprogramming to utilize anaerobic metabolic pathway via lactate dehydrogenase (LDH), enabling their survival. The goal of this project was to assess the growth response and rates of recurrence of HCC target and non-target (NT) tumors to transarterial embolization (TAE) with an LDH inhibitor (LDHi) as compared with bland TAE.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
